Insider Trading March 30, 2026

Neuronetics Insider Adds $675,000 in Shares as Company Reports Mixed Q4 Results

Jorey Chernett increases stake amid recent revenue beat, EPS miss and a reduced analyst price target

By Derek Hwang STIM
Neuronetics Insider Adds $675,000 in Shares as Company Reports Mixed Q4 Results
STIM

Jorey Chernett, a 10% holder of Neuronetics, purchased 500,000 shares on March 27, 2026, paying between $1.28 and $1.41 per share for a total outlay of $675,000. The trade leaves Chernett with 9,393,276 shares. The transaction comes alongside Neuronetics' fourth-quarter 2025 results, which showed revenue above forecasts but an EPS shortfall, and a lowered analyst price target that retains a Buy rating.

Key Points

  • Jorey Chernett bought 500,000 Neuronetics shares on March 27, 2026, spending $675,000 at $1.28 to $1.41 per share and now directly owns 9,393,276 shares.
  • Neuronetics reported Q4 2025 revenue of $41.8 million, beating the $40.66 million forecast by 2.73%, while EPS was -$0.10 versus an expected -$0.09, an 11.11% miss.
  • Canaccord lowered its price target from $7.00 to $3.00 but kept a Buy rating; Dan Reuvers was named CEO and the company said the second quarter was operationally cash flow positive.

Jorey Chernett, reported as a ten percent owner of Neuronetics, Inc. (NASDAQ: STIM), acquired 500,000 shares of the company’s common stock on March 27, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The purchases occurred in multiple transactions at prices spanning $1.28 to $1.41 per share, totaling $675,000.

Following the filings, Chernett’s direct ownership in Neuronetics stands at 9,393,276 shares. The shares are trading at $1.34 at the time of reporting, and an InvestingPro tip notes the stock declined 19% over the last week.

Those insider purchases come amid the company’s recently reported fourth-quarter 2025 results. Neuronetics posted revenue of $41.8 million for the quarter, topping the forecast of $40.66 million and producing a 2.73% positive surprise relative to expectations. Earnings per share for the period were -$0.10, however, missing the anticipated -$0.09 and creating an 11.11% negative surprise on the EPS line.

Corporate leadership and operational updates accompanied the quarterly disclosure. Neuronetics named Dan Reuvers as its new chief executive officer. The company also noted that the second quarter was operationally cash flow positive.

In coverage developments, Canaccord revised its price target for Neuronetics from $7.00 to $3.00, citing a shift in valuation, while retaining a Buy rating on the shares. For investors seeking additional analysis, the company’s Pro Research Report is referenced as a source for deeper financial detail and further InvestingPro tips.


Context and implications

The insider purchase and the company’s quarterly performance present a mixed picture: a significant insider acquisition at modest prices contrasts with an EPS miss and a material cut to an analyst price target, even as revenue modestly beat estimates and operational cash flow turned positive in the second quarter.

Investors evaluating Neuronetics may weigh the insider transaction alongside the earnings details, CEO transition, and the revised price guidance from at least one analyst. The recent share-price slide noted by InvestingPro is part of the near-term market backdrop.

Risks

  • Recent share-price volatility - the stock fell 19% over the past week, indicating short-term market risk for investors (impacts equity markets and small-cap healthcare stocks).
  • Earnings shortfall - the Q4 EPS missed expectations, representing profitability risk and potential pressure on valuation (impacts investor sentiment and healthcare devices sector).
  • Analyst valuation adjustment - a material cut in price target from $7.00 to $3.00 could signal lowered market valuation expectations and affect analyst-driven demand (impacts brokerage coverage and institutional interest).

More from Insider Trading

GlobalFoundries’ CLO Disposes of $22,995 in Stock as Company Faces Legal and Capital Moves Mar 30, 2026 Lemonade Director Increases Stake with $485k in Stock Purchases Mar 30, 2026 Horace Mann CMO Makes Modest Stock Purchase as Company Posts Strong Q4 Results Mar 30, 2026 IperionX President Purchases $262,552 in ADS as Coverage Begins and Production Ramps Mar 30, 2026 LightPath CEO Makes Small Personal Purchase as Company Posts Revenue Beat but EPS Misses Mar 30, 2026